Online inquiry

IVTScrip™ mRNA-Anti-VTCN1, FPA-150(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7342MR)

This product GTTS-WQ7342MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets VTCN1 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001253849.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 79679
UniProt ID Q7Z7D3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VTCN1, FPA-150(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7342MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5051MR IVTScrip™ mRNA-Anti-C5, CaCP-29(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CaCP-29
GTTS-WQ15105MR IVTScrip™ mRNA-Anti-TNC, ST2146(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ST2146
GTTS-WQ8512MR IVTScrip™ mRNA-Anti-B4GALNT1, Hu3F8(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA Hu3F8
GTTS-WQ13935MR IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-2810
GTTS-WQ11546MR IVTScrip™ mRNA-Anti-CD3E, MGA031(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MGA031
GTTS-WQ5340MR IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CD38-Attenukine
GTTS-WQ14200MR IVTScrip™ mRNA-Anti-IL17A, RG4934(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA RG4934
GTTS-WQ2085MR IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AIN457
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW